Abstract
AbstractThe addition of low-dose tricyclic antidepressant (e.g., 10-50 mg of DMI) was employed as a treatment adjunct for 20 outpatients with major depressive disorder and/or dysthymia whose response to fluoxetine alone had been inadequate. Retrospective assessment revealed complete resolution of depression (full response) in 13 patients (65%) after adjunct was added. Improvement was evident within seven days of introduction of the adjunct in seven of the responders (54.8%). One patient worsened, experiencing increased agitation. No treatment-emergent side effects were observed in the other 19 patients. TCA plasma levels obtained in nine patients while combination treatment was ongoing were higher than would be expected for that dose of TCA used alone, but none of the levels were in the toxic range.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
